Comparison of survival outcomes among cancer patients treated in and out of clinical trials

Joseph M. Unger, William E. Barlow, Diane P. Martin, Scott D. Ramsey, Michael LeBlanc, Ruth Etzioni, Dawn L. Hershman

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Background Clinical trials test the efficacy of a treatment in a select patient population. We examined whether cancer clinical trial patients were similar to nontrial, "real-world" patients with respect to presenting characteristics and survival. Methods We reviewed the SWOG national clinical trials consortium database to identify candidate trials. Demographic factors, stage, and overall survival for patients in the standard arms were compared with nontrial control subjects selected from the Surveillance, Epidemiology, and End Results program. Multivariable survival analyses using Cox regression were conducted. The survival functions from aggregate data across all studies were compared separately by prognosis (=50% vs <50% average 2-year survival). All statistical tests were two-sided. Results We analyzed 21 SWOG studies (11 good prognosis and 10 poor prognosis) comprising 5190 patients enrolled from 1987 to 2007. Trial patients were younger than nontrial patients (P < .001). In multivariable analysis, trial participation was not associated with improved overall survival for all 11 good-prognosis studies but was associated with better survival for nine of 10 poor-prognosis studies (P < .001). The impact of trial participation on overall survival endured for only 1 year. Conclusions Trial participation was associated with better survival in the first year after diagnosis, likely because of eligibility criteria that excluded higher comorbidity patients from trials. Similar survival patterns between trial and nontrial patients after the first year suggest that trial standard arm outcomes are generalizable over the long term and may improve confidence that trial treatment effects will translate to the real-world setting. Reducing eligibility criteria would improve access to clinical trials.

Original languageEnglish (US)
Article numberdju002
JournalJournal of the National Cancer Institute
Volume106
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Clinical Trials
Survival
Neoplasms
SEER Program
Survival Analysis
Comorbidity
Demography
Databases
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Unger, J. M., Barlow, W. E., Martin, D. P., Ramsey, S. D., LeBlanc, M., Etzioni, R., & Hershman, D. L. (2014). Comparison of survival outcomes among cancer patients treated in and out of clinical trials. Journal of the National Cancer Institute, 106(3), [dju002]. https://doi.org/10.1093/jnci/dju002

Comparison of survival outcomes among cancer patients treated in and out of clinical trials. / Unger, Joseph M.; Barlow, William E.; Martin, Diane P.; Ramsey, Scott D.; LeBlanc, Michael; Etzioni, Ruth; Hershman, Dawn L.

In: Journal of the National Cancer Institute, Vol. 106, No. 3, dju002, 01.01.2014.

Research output: Contribution to journalArticle

Unger, JM, Barlow, WE, Martin, DP, Ramsey, SD, LeBlanc, M, Etzioni, R & Hershman, DL 2014, 'Comparison of survival outcomes among cancer patients treated in and out of clinical trials', Journal of the National Cancer Institute, vol. 106, no. 3, dju002. https://doi.org/10.1093/jnci/dju002
Unger, Joseph M. ; Barlow, William E. ; Martin, Diane P. ; Ramsey, Scott D. ; LeBlanc, Michael ; Etzioni, Ruth ; Hershman, Dawn L. / Comparison of survival outcomes among cancer patients treated in and out of clinical trials. In: Journal of the National Cancer Institute. 2014 ; Vol. 106, No. 3.
@article{de1f3672bfed402fb0fd8ec2036cc81b,
title = "Comparison of survival outcomes among cancer patients treated in and out of clinical trials",
abstract = "Background Clinical trials test the efficacy of a treatment in a select patient population. We examined whether cancer clinical trial patients were similar to nontrial, {"}real-world{"} patients with respect to presenting characteristics and survival. Methods We reviewed the SWOG national clinical trials consortium database to identify candidate trials. Demographic factors, stage, and overall survival for patients in the standard arms were compared with nontrial control subjects selected from the Surveillance, Epidemiology, and End Results program. Multivariable survival analyses using Cox regression were conducted. The survival functions from aggregate data across all studies were compared separately by prognosis (=50{\%} vs <50{\%} average 2-year survival). All statistical tests were two-sided. Results We analyzed 21 SWOG studies (11 good prognosis and 10 poor prognosis) comprising 5190 patients enrolled from 1987 to 2007. Trial patients were younger than nontrial patients (P < .001). In multivariable analysis, trial participation was not associated with improved overall survival for all 11 good-prognosis studies but was associated with better survival for nine of 10 poor-prognosis studies (P < .001). The impact of trial participation on overall survival endured for only 1 year. Conclusions Trial participation was associated with better survival in the first year after diagnosis, likely because of eligibility criteria that excluded higher comorbidity patients from trials. Similar survival patterns between trial and nontrial patients after the first year suggest that trial standard arm outcomes are generalizable over the long term and may improve confidence that trial treatment effects will translate to the real-world setting. Reducing eligibility criteria would improve access to clinical trials.",
author = "Unger, {Joseph M.} and Barlow, {William E.} and Martin, {Diane P.} and Ramsey, {Scott D.} and Michael LeBlanc and Ruth Etzioni and Hershman, {Dawn L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1093/jnci/dju002",
language = "English (US)",
volume = "106",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Comparison of survival outcomes among cancer patients treated in and out of clinical trials

AU - Unger, Joseph M.

AU - Barlow, William E.

AU - Martin, Diane P.

AU - Ramsey, Scott D.

AU - LeBlanc, Michael

AU - Etzioni, Ruth

AU - Hershman, Dawn L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background Clinical trials test the efficacy of a treatment in a select patient population. We examined whether cancer clinical trial patients were similar to nontrial, "real-world" patients with respect to presenting characteristics and survival. Methods We reviewed the SWOG national clinical trials consortium database to identify candidate trials. Demographic factors, stage, and overall survival for patients in the standard arms were compared with nontrial control subjects selected from the Surveillance, Epidemiology, and End Results program. Multivariable survival analyses using Cox regression were conducted. The survival functions from aggregate data across all studies were compared separately by prognosis (=50% vs <50% average 2-year survival). All statistical tests were two-sided. Results We analyzed 21 SWOG studies (11 good prognosis and 10 poor prognosis) comprising 5190 patients enrolled from 1987 to 2007. Trial patients were younger than nontrial patients (P < .001). In multivariable analysis, trial participation was not associated with improved overall survival for all 11 good-prognosis studies but was associated with better survival for nine of 10 poor-prognosis studies (P < .001). The impact of trial participation on overall survival endured for only 1 year. Conclusions Trial participation was associated with better survival in the first year after diagnosis, likely because of eligibility criteria that excluded higher comorbidity patients from trials. Similar survival patterns between trial and nontrial patients after the first year suggest that trial standard arm outcomes are generalizable over the long term and may improve confidence that trial treatment effects will translate to the real-world setting. Reducing eligibility criteria would improve access to clinical trials.

AB - Background Clinical trials test the efficacy of a treatment in a select patient population. We examined whether cancer clinical trial patients were similar to nontrial, "real-world" patients with respect to presenting characteristics and survival. Methods We reviewed the SWOG national clinical trials consortium database to identify candidate trials. Demographic factors, stage, and overall survival for patients in the standard arms were compared with nontrial control subjects selected from the Surveillance, Epidemiology, and End Results program. Multivariable survival analyses using Cox regression were conducted. The survival functions from aggregate data across all studies were compared separately by prognosis (=50% vs <50% average 2-year survival). All statistical tests were two-sided. Results We analyzed 21 SWOG studies (11 good prognosis and 10 poor prognosis) comprising 5190 patients enrolled from 1987 to 2007. Trial patients were younger than nontrial patients (P < .001). In multivariable analysis, trial participation was not associated with improved overall survival for all 11 good-prognosis studies but was associated with better survival for nine of 10 poor-prognosis studies (P < .001). The impact of trial participation on overall survival endured for only 1 year. Conclusions Trial participation was associated with better survival in the first year after diagnosis, likely because of eligibility criteria that excluded higher comorbidity patients from trials. Similar survival patterns between trial and nontrial patients after the first year suggest that trial standard arm outcomes are generalizable over the long term and may improve confidence that trial treatment effects will translate to the real-world setting. Reducing eligibility criteria would improve access to clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84898744858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898744858&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju002

DO - 10.1093/jnci/dju002

M3 - Article

VL - 106

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

M1 - dju002

ER -